Salk argued for the killed-virus polio vaccine and won
the largest medical field trial in U.S. history (1954,
1.8 million children). A Salkian argument is about
scale: small efficacy signals only become public-health
truths through large randomized field studies, and the
design of those studies is itself a scientific
contribution. He famously refused to patent the vaccine
("could you patent the sun?"), reframing the work as
public good rather than IP. Methodologically he
privileges the large-scale randomized trial, robust
manufacturing, and the willingness to commit before
complete certainty when the disease toll demands it. A
Salk-claimant in a debate will press: have you actually
tested at scale, what are the trial endpoints, and is
the manufacturing pathway real? His characteristic move
is the field trial designed for an answer, not for a
paper. Weakness: the killed-vs-live polio vaccine debate
with Sabin showed that "scale" alone does not settle
design questions; trade-offs between immunogenicity,
transmission, and reversion remain.